<DOC>
	<DOCNO>NCT01124812</DOCNO>
	<brief_summary>The aim feasibility study determine therapeutic potential L19SIP antibody , label radionuclide 131I combination radiochemotherapy , treatment patient newly diagnose , unresectable , locally-advanced NSCLC follow promising result agent previous clinical study . The L19SIP antibody fully human antibody , capable preferential localization around tumor blood vessel spar normal tissue . The formation new blood vessel rare event adult ( exception female reproductive tract ) , characteristic pathological feature type aggressive cancer .</brief_summary>
	<brief_title>131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy Patients With Locally-advanced Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically confirm unresectable stage III NSCLC Males female , age ≥ 18 year Measurable lung lesion define least one lesion accurately serially measure per modify RECIST criterion . ECOG performance status &lt; 3 Life expectancy least 12 week Patients eligible concurrent radiochemotherapy ( cisplatin/vinorelbine ; 6066 Gy EBRT ) discretion clinical investigator Absolute neutrophil count &gt; 1.5 x 109/L , hemoglobin &gt; 9.0 g/dL platelet &gt; 100 x 109/L Total bilirubin ≤ 30 µmol/L ( ≤ 2.0 mg/Dl ) ALT AST ≤ 2.5 x upper limit normal ( 5.0 x ULN patient hepatic involvement tumor Serum creatinine &lt; 1.5 x ULN All toxic effect prior therapy must resolve ≤ Grade 1 unless otherwise specify Negative serum pregnancy test ( woman childbearing potential ) screen Patients metastatic disease Patients amenable surgical resection lung tumor lesion Previous concurrent cancer distinct primary site histology cancer evaluate study except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( TA , Tis &amp; Ti ) cancer curatively treat &lt; 5 year prior study entry History HIV infection infectious hepatitis B C Presence active infection ( e.g . require antibimicrobial therapy ) severe concurrent disease , , opinion investigator , would place patient undue risk interfere study . Inadequately controlled cardiac arrhythmia include atrial fibrillation Heart insufficiency ( &gt; Grade II , New York Heart Association ( NYHA ) criterion ) Uncontrolled hypertension Ischemic peripheral vascular disease ( Grade IIbIV ) History acute cardiac event myocardial infarction , instable angina pectoris last 12 month Severe diabetic retinopathy Active autoimmune disease History organ allograft stem cell transplantation Recovery major trauma include surgery within 4 week prior administration study treatment Breast feed female Previous vivo exposure monoclonal antibody biological therapy 6 week administration study treatment Growth factor immunomodulatory agent within 7 day administration study treatment ( 131IL19SIP application ) . Hyperthyroidism autonomous thyroid nodule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>I131</keyword>
	<keyword>L19</keyword>
	<keyword>antibody</keyword>
	<keyword>monoclonal</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung</keyword>
	<keyword>tumor target</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>Patients newly diagnose inoperable , locally-advanced ( stage III ) NSCLC</keyword>
</DOC>